Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | |
|---|---|---|---|---|---|---|---|
| 1 | 5 | 4 | for | 9 | up | 7 | |
| 2 | 9 | patient must be | 3 | for the duration of the study and are willing to | 6 | study procedures | 4 |
| 3 | 12 | are reliable and willing to make themselves | 3 | for complete documentation of the treatment response assessment adverse events and | 2 | up . | 2 |
| 4 | 1 | patients must be accessible for treatment and follow up . patients registered on this trial must receive protocol treatment and be followed at the participating center . this implies there must be reasonable geographical limits placed on patients being considered for this trial . investigators must ensure that the patients randomized on this trial will be | 2 | for complete documentation of the treatment adverse events and | 2 | study specific procedures . | 2 |
| 5 | 3 | reliable and willing to make themselves | 2 | patients < 0 . 73 m 2 must | 1 | up over the course of the study | 2 |
| 6 | 19 | patients not | 2 | during the duration of the study and willing to | 1 | the dosing nomogram patients > = 0 . 73 m 2 at enrollment must follow the dosing nomogram | 1 |
| 7 | 2 | patients must have a body surface area > = 0 . 37 m 2 at enrollment while the 120 mg strength tablet supply is | 1 | for long term | 1 | the study procedures | 1 |
| 8 | 7 | patients must be accessible for treatment and follow up . investigators must assure themselves the patients randomized on this trial will be | 1 | for study | 1 | up of their disease after treatment | 1 |
| 9 | 8 | must be | 1 | for the duration of the study and willing to | 1 | up after 2 years of follow up following post treatment biopsy telephone based follow up will be acceptable | 1 |
| 10 | 16 | patients who in the opinion of the investigator womcLd not be able to provide reliable study data or be | 1 | for 6 weeks of treatment and 6 months of | 1 | study procedures . | 1 |
| 11 | 17 | patients must be accessible for treatment and follow up investigators must assure themselves the patients randomized on this trial will be | 1 | NA | up testing | 1 | |
| 12 | 18 | reliable and | 1 | NA | up tests | 1 | |
| 13 | 21 | subject will not be | 1 | NA | up assessment | 1 | |
| 14 | 23 | not | 1 | NA | NA | ||
| 15 | 24 | agree to participate in the study and be | 1 | NA | NA |